Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Nov;34(11):e682-e684.
doi: 10.1111/jdv.16771. Epub 2020 Jul 9.

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic

F Rob  1 , J Hugo  2 , S Tivadar  2 , P Boháč  1 , S Gkalpakiotis  2 , N Vargová  1 , M Arenbergerová  2 , J Hercogová  1
Affiliations
Multicenter Study

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic

F Rob et al. J Eur Acad Dermatol Venereol. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

FR has received honoraria as a speaker and/or consultant for AbbVie, Celgene, Eli Lilly, Janssen, MSD, Novartis, Sanofi Genzyme, UCB. JH has received honoraria as a speaker and/or consultant for Novartis, LEO Pharma, Janssen, Eli Lilly, Sandoz, Celgene, Eucerin. ST has no conflict of interest. PB has received honoraria as a speaker and/or consultant for Eli Lilly, Janssen, Novartis, Leo Pharma. SG has received honoraria as a speaker and/or consultant for AbbVie, Celgene, Eli Lilly, Janssen, MSD, Novartis, Sanofi Genzyme, UCB, Leo Pharma. NV has received honoraria as a speaker for Novartis. MA reports fees for Advisory Boards from Abbvie, BMS. JH has received honoraria as a speaker and/or consultant for AbbVie, Celgene, Eli Lilly, Frankl Pharma, Janssen, Leo Pharma, Novartis, Novartis Global, Sanofi Aventis and Sanofi Genzyme.

Figures

Figure 1
Figure 1
Patients' response to the statement, ‘I feel an increased risk of infection (complications) from coronavirus (COVID‐19) because of the type of treatment for my psoriasis’.
See this image and copyright information in PMC

References

    1. Lebwohl M, Rivera‐Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID‐19? J Am Acad Dermatol 2020; 82: 1217–1218. - PMC - PubMed
    1. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID‐19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther 2020; e13298. https://di.org/10.1111/dth.13298 - DOI - PMC - PubMed
    1. Julian LJ. Measures of anxiety: state‐trait anxiety inventory (STAI), Beck anxiety inventory (BAI), and Hospital anxiety and Depression scale‐anxiety (HADS‐A). Arthritis Care Res 2011; 63: S467–S472. - PMC - PubMed
    1. Vangeli E, Bakhshi S, Baker A et al. A systematic review of factors associated with non‐adherence to treatment for immune‐mediated inflammatory diseases. Adv Ther 2015; 32: 983–1028. - PMC - PubMed
    1. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population‐based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol 2016; 17: 87–97. - PMC - PubMed

MeSH terms

Substances